$REGN Securities: Suffer Losses on Your Regeneron Investment? BFA Law Reminds Investors of the Securities Fraud Lawsuit to Recover Losses

A securities fraud class action lawsuit has been filed against Regeneron Pharmaceuticals for allegedly misleading investors about the success of its Phase III Fianlimab-Libtayo clinical trial. The stock dropped 6.2% on April 29, 2026, and 9.8% on May 15, 2026, after the company announced the study failed to achieve statistical significance. Investors have until September 14, 2026, to request lead plaintiff status.

07/31/2026, 6:46 AM • GlobeNewswire

REGN ALERT: Hagens Berman Alerts Regeneron Pharmaceuticals, Inc. (REGN) Investors to Pending Securities Class Action Amid Disclosures About Key Trial’s Protocol and Ultimate Failure

Regeneron Pharmaceuticals faces a securities class action lawsuit after failing to disclose critical information about its Phase 3 clinical trial for a melanoma treatment combination therapy. The company allegedly made misleading statements about the trial's progress while concealing that preliminary statistical assumptions were flawed and the primary endpoint was unlikely to be achieved. The trial ultimately failed to reach statistical significance, resulting in an $11 billion market cap loss. The class period covers August 1, 2025 to May 15, 2026, with a lead plaintiff deadline of September 14, 2026.

07/30/2026, 7:49 PM • GlobeNewswire

Bronstein, Gewirtz & Grossman LLC Urges Regeneron Pharmaceuticals, Inc. Investors to Act: Class Action Filed Alleging Investor Harm

A class action lawsuit has been filed against Regeneron Pharmaceuticals alleging securities fraud. The complaint claims the company made false statements about its Phase III Fianlimab-Libtayo study, including flawed statistical assumptions and failure to disclose that the study was unlikely to achieve its primary endpoint. Investors who purchased Regeneron securities between August 1, 2025 and May 15, 2026 are eligible to join the case.

07/29/2026, 12:00 PM • GlobeNewswire

Portnoy Law Firm Announces Class Action on Behalf of Regeneron Pharmaceuticals, Inc. Investors

The Portnoy Law Firm has filed a class action lawsuit on behalf of Regeneron Pharmaceuticals investors who purchased securities between August 1, 2025 and May 15, 2026. The lawsuit alleges that Regeneron made false statements about its Phase III Fianlimab-Libtayo clinical trial, misrepresenting the study's prospects while downplaying risks. The trial ultimately failed to reach statistical significance on its primary endpoint, causing Regeneron's stock to drop approximately 10% on May 15, 2026.

07/27/2026, 9:38 AM • GlobeNewswire

Regeneron Pharmaceuticals, Inc. (REGN) Faces Securities Class Action Amid Disclosures About Key Trial’s Protocol and Ultimate Failure - HBSS

Regeneron Pharmaceuticals faces a securities class action lawsuit after failing to disclose critical information about its Phase 3 clinical trial for a melanoma treatment combination. The company allegedly made misleading statements about the trial's progress while concealing that preliminary statistical assumptions were flawed and the primary endpoint was unlikely to be achieved. The trial ultimately failed to reach statistical significance on May 15, 2026, resulting in an $11 billion market cap loss. The lawsuit covers investors who purchased shares between August 1, 2025 and May 15, 2026.

07/24/2026, 2:22 PM • GlobeNewswire

Telix Q2 Revenue US$247M, Strong Momentum and Pipeline Progress

Telix Pharmaceuticals reported Q2 2026 group revenue of US$247 million (up 7% QoQ, 21% YoY) with Precision Medicine revenue reaching US$202 million (up 30% YoY). The company achieved key regulatory milestones including FDA alignment on TLX591-Tx Phase 3 trial progression and near-completion of BiPASS patient enrollment. FY 2026 revenue guidance remains on track to exceed US$1 billion. Telix also entered a strategic collaboration with Regeneron and completed a convertible bond refinancing.

07/20/2026, 7:31 PM • GlobeNewswire

Bronstein, Gewirtz & Grossman LLC Urges Regeneron Pharmaceuticals, Inc. Investors to Act: Class Action Filed Alleging Investor Harm

A class action lawsuit has been filed against Regeneron Pharmaceuticals alleging securities fraud. The complaint claims the company made materially false statements regarding its Phase III Fianlimab-Libtayo study, including flawed statistical assumptions and failure to disclose that the study was unlikely to achieve its primary endpoint. Investors who purchased Regeneron securities between August 1, 2025 and May 15, 2026 are eligible to join the case.

07/19/2026, 12:00 PM • GlobeNewswire

Clinical Stage Partnering Terms and Agreements in Pharmaceuticals and Biotechnology 2020-2026 | Benchmark More Than 1,800 Biopharma Deals with Various Indexes

ResearchAndMarkets.com released a comprehensive report analyzing over 1,859 clinical-stage pharmaceutical and biotechnology partnership deals announced since 2020. The report provides detailed financial terms, deal structures, contract documents, and insights into negotiation dynamics for clinical-stage drug development collaborations, serving as a benchmarking resource for biopharma dealmakers.

07/17/2026, 6:48 AM • GlobeNewswire

Autoimmune Disease Therapeutics Market Size to Reach USD 137.85 Billion by 2035 as Biologics and Precision Medicine Drive Growth | SNS Insider

The global autoimmune disease therapeutics market is projected to grow from USD 80.54 billion in 2025 to USD 137.85 billion by 2035, with a CAGR of 5.52%. Growth is driven by rising prevalence of autoimmune diseases, adoption of biologics, JAK inhibitors, monoclonal antibodies, and precision medicine technologies. North America leads with 39.96% market share, while Asia-Pacific shows the fastest growth at 6.28% CAGR.

07/15/2026, 11:00 AM • GlobeNewswire

Dupilumab Achieves Record $11.9 Billion in Global Sales Amidst Continued Growth

Dupilumab (Dupixent) continues strong growth with €10.7 billion in 2023 sales and $4.34 billion in Q2 2025. FDA approval for COPD in September 2024 and expansion to chronic spontaneous urticaria in children unlock new market opportunities. The drug demonstrates clinical superiority over competitors like Xolair, with market projections extending to 2034 across multiple indications and geographic regions.

07/03/2026, 4:40 AM • GlobeNewswire

Wall Street Thinks This Biotech Stock Can Soar 45%. Here's Why Analysts Are Right.

Alnylam Pharmaceuticals has gained strong analyst support with 21 of 29 analysts rating it as buy or strong buy, with an average price target of $436 (45% upside). The company is transitioning from a clinical biotech to a profitable commercial powerhouse, with Q1 product revenue surging 121% year-over-year to $1.04 billion, driven by its ATTR franchise. The company's pipeline is expanding into mainstream markets like cardiomyopathy and hypertension, supported by a unique RNAi delivery platform that creates a competitive moat. However, the stock trades at a high valuation of 75x trailing earnings, with risks from competitive pricing pressure.

07/02/2026, 6:33 AM • The Motley Fool

Questex’s PODD, the Premier Gathering for Drug Delivery Industry Leaders, Announces the 16th Annual Conference Agenda

Questex's Fierce Life Sciences announced the agenda for the 16th annual PODD (Partnership Opportunities in Drug Delivery) Conference, scheduled for October 29-30, 2026, in Boston. The event will gather over 1,000 industry executives and features 150+ sessions with keynotes from Regeneron's Dr. George Yancopoulos and MIT's Dr. Robert Langer, covering topics including AI in drug delivery, pharma partnering strategies, and reimbursement challenges.

06/23/2026, 8:00 AM • GlobeNewswire

AbbVie's $10.9 Billion Apogee Deal Will Extend Its Immunology Dominance: Is It Time to Load Up on This Dividend King?

AbbVie announced a $10.9 billion acquisition of clinical-stage biotech Apogee Therapeutics, paying $135.11 per share in cash. The deal strengthens AbbVie's immunology portfolio with access to promising drug candidates like zumilokibart for eczema and asthma. While the acquisition will create near-term EPS headwinds, analysts expect it to be accretive by 2032 and support AbbVie's dividend yield of over 3%.

06/22/2026, 6:36 PM • The Motley Fool

Intellia Therapeutics vs. Omeros: Which Emerging Biotech Stock Is a Better Buy in 2026?

The article compares two emerging biotech stocks: Intellia Therapeutics, which focuses on CRISPR gene-editing technology with promising Phase III trial data but significant losses and clinical risks, and Omeros, which recently achieved FDA approval for Yartemlea and posted its first commercial revenue of $9.89 million. While Intellia offers higher upside potential, Omeros is deemed the safer choice due to its transition to profitability, strong initial sales, and healthier balance sheet, despite trading at a premium valuation.

06/20/2026, 11:02 AM • The Motley Fool

This Stock Is Up 58% This Year. Is It too Late to Buy?

Intellia Therapeutics' stock has surged 58% year-to-date following positive phase 3 trial results for lonvo-z, a gene-editing treatment for hereditary angioedema. While lonvo-z shows promise with an 87% reduction in attacks, its commercial opportunity is limited to a small patient population (~7,000 in the U.S.), potentially generating $3.5 billion in lifetime sales. The company's more promising pipeline candidate, nex-z for transthyretin amyloidosis, won't show results until 2027. Investors should weigh significant clinical and regulatory risks against potential upside.

06/17/2026, 2:30 AM • The Motley Fool